Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05591079 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
A Phase 2 study of Nonalcoholic Steatohepatitis (NASH), sponsored by Cascade Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 17
- Study locations
NCT05591079 is a Phase 2 study of Nonalcoholic Steatohepatitis (NASH) that has completed, run by Cascade Pharmaceuticals. The registered enrollment target is 99 participants, below the 112-participant average among 6 other Nonalcoholic Steatohepatitis (NASH) trials with a reported enrollment target (12% lower). The trial reports 17 study locations across 7 states.
The verdict
NCT05591079, a Phase 2 study of Nonalcoholic Steatohepatitis (NASH), has completed, sponsored by Cascade Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 17
- Study locations
Study Summary
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
Conditions Studied
Interventions
- DRUG CS0159 (Linafexor)
Study Locations (17)
Florida
- Ocala GI Research - Lady Lake
- Florida Research Institute - Lakewood
- San Marcus Research Clinic, Inc - Miami - Miami
- Floridian Clinical Research, LLC - Miami Lakes - Miami Lakes
- Gastroenterology Associates of Ocala - Ocala
California
- National Research Institute - Gardena - Gardena
- Velocity Clinical Research, Huntington Park - Huntington Park
- Velocity Clinical Research - Panorama City - Panorama City
- Velocity Clinical Research - Santa Ana - Santa Ana
Texas
- Texas Liver Institute (TLI) - Austin - Austin
- Pioneer Research Solutions Inc - Houston - Stancliff Rd - Houston
- The Texas Liver Institute, Inc. - San Antonio
- Clinical Trials of Texas, LLC - San Antonio
Georgia
- Oracle Clinical Research - College Park
Louisiana
- Metropolitan Gastroenterology Associates - Westbank Office and Endoscopy - Marrero
Maryland
- Raja M. Din MD, PLLC - Gastroenterology & Hepatology - Greenbelt
North Carolina
- Lucas Research - Morehead City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2023-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05591079
The ClinicalTrials.gov registry entry for NCT05591079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 6 other Nonalcoholic Steatohepatitis (NASH) trials with a reported enrollment target (12% lower). The listed sponsor is Cascade Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nonalcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 1 intervention - of which CS0159 (Linafexor) is the first listed.
NCT05591079 reports 17 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05591079 about?
NCT05591079 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH". A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
What is the current status of trial NCT05591079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2023-02-10. Estimated completion is 2023-11-09.
What conditions does trial NCT05591079 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis (NASH).
What interventions are being tested in trial NCT05591079?
The interventions under investigation include: CS0159 (Linafexor) (DRUG).
Who is sponsoring clinical trial NCT05591079?
This trial is sponsored by Cascade Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05591079 being conducted?
This trial has 17 study locations across California, Florida, Georgia, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
COMPLETED · Phase 2
-
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
RECRUITING · Phase 1
-
Tesamorelin Effects on Liver Fat and Histology in HIV
COMPLETED · NA
-
Feasibility of VIIT in Adults With NASH
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.